Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S (ASND) delivers innovative biopharmaceutical solutions through its proprietary TransCon platform, focusing on rare endocrine disorders, oncology, and growth-related conditions. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access timely reports on ASND's product pipeline including TransCon PTH for hypoparathyroidism and TransCon CNP for achondroplasia. Our curated news collection covers earnings announcements, partnership developments, and European Medicines Agency (EMA)/FDA regulatory interactions, offering critical context for understanding the company's growth trajectory.
Key updates include progress in global clinical trials, manufacturing expansions, and analyses of commercial strategies for approved therapies. Bookmark this page for consolidated access to verified press releases and objective third-party analyses of ASND's position in the competitive biopharma landscape.
Ascendis Pharma A/S (Nasdaq: ASND) has submitted a Biologics License Application (BLA) for TransCon™ hGH to the FDA for pediatric growth hormone deficiency, with a European Marketing Authorisation Application (MAA) planned for Q3 2020 after EMA approval of the Pediatric Investigation Plan. New trial data showed TransCon PTH significantly improved quality of life for hypoparathyroidism patients. The company reported a Q2 2020 net loss of €94.9 million, a decline from €58.9 million in Q2 2019, with revenue decreasing to €1.4 million from €3.2 million. Cash reserves total €471.6 million.
Ascendis Pharma A/S (Nasdaq: ASND) announced a conference call on August 27, 2020, at 4:30 PM ET to discuss its Q2 2020 financial results and provide a business update. The live webcast will be accessible on the company’s website, with a replay available for 30 days post-event. Ascendis is focused on developing therapies using its TransCon™ technologies, currently advancing three endocrinology product candidates and expanding into oncology. The company emphasizes patient needs and scientific innovation in its mission.
Ascendis Pharma A/S (Nasdaq: ASND) announced that the European Commission has granted Orphan Designation to its investigational drug, TransCon C-Type Natriuretic Peptide (CNP), for treating achondroplasia. This designation highlights the urgency for effective therapies for this condition, which affects about 250,000 people globally. TransCon CNP received similar status in the U.S. in February 2019. The company's ongoing Phase 2 ACcomplisH Trial aims to develop new treatment options, emphasizing the significance of CNP in promoting bone growth affected by the FGFR3 mutation.
Ascendis Pharma A/S (Nasdaq: ASND) announced the pricing of a public offering of 4,225,352 American Depositary Shares (ADSs) at $142.00 each, aiming to raise approximately $569.2 million. The funds will support clinical development and regulatory approval for TransCon hGH and other endocrinology programs, as well as working capital. The offering is expected to close on or about July 10, 2020, with an option for underwriters to purchase an additional 633,802 ADSs. J.P. Morgan, Morgan Stanley, and others are managing the offering.
Ascendis Pharma A/S (Nasdaq: ASND) announced a public offering of $500 million in American Depositary Shares (ADSs), each representing one ordinary share. A 30-day option for underwriters to purchase up to an additional $75 million is also expected. The offering is subject to market conditions and may vary in terms of size and completion. J.P. Morgan, Morgan Stanley, Evercore, and SVB Leerink are managing the offering. The company aims to address unmet medical needs through its innovative TransCon™ technologies and has a pipeline focused on endocrinology and oncology.
Ascendis Pharma A/S (ASND) announced receiving a positive opinion from the Paediatric Committee of the EMA for its TransCon hGH, a treatment for growth hormone deficiency in children aged 6 months to less than 18 years. This opinion supports the completion of the Paediatric Investigation Plan (PIP) based on extensive non-clinical and clinical trial data. The company is set to submit its European marketing application in Q3 2020, with no additional studies required. This marks a potential advancement in the long-acting growth hormone treatment for pediatric patients.
Ascendis Pharma A/S (Nasdaq: ASND) announced the submission of a Biologics License Application (BLA) for TransCon hGH, a long-acting treatment for pediatric growth hormone deficiency (GHD). This marks the first product candidate from the company's innovative TransCon technology to reach BLA submission after multiple Phase 3 trials. TransCon hGH, with orphan designation in the U.S. and Europe, aims to improve patient adherence by replacing daily injections. Future plans include a Marketing Authorisation Application to the European Medicines Agency and further trials in Japan and Greater China.
Ascendis Pharma A/S (Nasdaq: ASND) presented findings from its rare disease endocrinology programs at ENDO Online 2020. The fliGHt Trial showed that patients can safely switch from daily somatropin to TransCon hGH, maintaining consistent efficacy. Interim data from the heiGHt Trial reaffirmed height advantages beyond one year of therapy. The company plans to submit marketing applications in the U.S. this quarter and in Europe by Q3. Additionally, promising data for TransCon PTH highlights its potential as a replacement therapy for hypoparathyroidism.
Ascendis Pharma (ASND) reported its Q1 2020 financial results, revealing a net loss of €63.3 million, or €1.32 per share, versus €53.6 million, or €1.24 per share, in Q1 2019. Revenue dropped to €2.2 million from €5.4 million year-over-year, primarily due to decreased license and service revenue. The company is on track to file a Biologics License Application for TransCon hGH in Q2 and advance its European submission to Q3. Ascendis Pharma ended Q1 with €534.4 million in cash, a decrease from €598.1 million at the end of 2019. R&D expenses rose to €57.5 million, reflecting ongoing product development efforts.
Ascendis Pharma A/S (NASDAQ: ASND) announced a conference call and live webcast on May 19, 2020, at 4:30 p.m. ET to discuss its Q1 2020 financial results and provide a business update. The call can be accessed via a dial-in number or through the company's website, where a replay will be available for 30 days following the event. Ascendis Pharma focuses on innovative therapies using its TransCon™ platform, with ongoing clinical development in endocrinology and oncology.
